Astera Labs (NASDAQ:ALAB) Trading 2.1% Higher - What's Next?

Key Points

• Astera Labs shares rose 2.1% on Friday, trading as high as $203.50 after closing at $195.65, with volume below its daily average.
• Analysts turned more bullish after the company’s results, with JPMorgan raising its price target to $280 and Needham lifting its target to $260; the overall consensus remains a “Moderate Buy.”
• Recent earnings showed strong growth, as Astera Labs reported Q1 EPS of $0.61 versus $0.54 expected and revenue of $308.36 million, up 93.5% year over year, while Q2 guidance also came in solid.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) shares shot up 2.1% during trading on Friday . The company traded as high as $203.50 and last traded at $199.79. 4,479,711 shares changed hands during mid-day trading, a decline of 17% from the average session volume of 5,385,805 shares. The stock had previously closed at $195.65.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Astera Labs to $280 from $205 and kept an overweight rating, signaling strong confidence in further upside after the company’s latest results. Benzinga
• Positive Sentiment: Needham lifted its price target to $260, while other reports cited positive forecasts from JPMorgan and Stifel, adding to the bullish analyst momentum around ALAB. Astera Labs NASDAQ: ALAB Price Target Raised to $260.00 at Needham & Company LLC
• Positive Sentiment: Commentary around the stock highlighted Astera Labs as a long-term momentum name and a beneficiary of AI connectivity demand, suggesting investors see durable growth tied to datacenter buildouts and server interconnect products. Why Astera Labs, Inc. (ALAB) is a Top Momentum Stock for the Long-Term
• Positive Sentiment: Several pieces emphasized strong AI connectivity demand and Scorpio expansion, with upbeat takes on the company’s positioning in the datacenter market helping support the stock. Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised
• Neutral Sentiment: Post-earnings analysis was mixed: bulls pointed to strong growth, but critics noted rising costs, competition, and a premium valuation, which could cap near-term upside. Should Investors Buy, Hold, or Sell ALAB Stock Post Q1 Earnings?
• Neutral Sentiment: Astera Labs’ Q1 2026 earnings transcript kept attention on the company’s strong revenue growth and guidance, but the transcript itself does not add a new catalyst beyond the already reported results. Astera Labs (ALAB) Q1 2026 Earnings Transcript
• Negative Sentiment: The main downside risk is valuation: after a strong run and multiple target hikes, some investors may worry the stock already prices in a lot of future growth.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALAB. Needham & Company LLC upped their target price on shares of Astera Labs from $220.00 to $260.00 and gave the company a "buy" rating in a report on Wednesday. Weiss Ratings raised Astera Labs from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday. Barclays upped their price objective on Astera Labs from $165.00 to $200.00 and gave the company an "equal weight" rating in a research note on Thursday. Citigroup raised their price objective on Astera Labs from $200.00 to $245.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Rothschild & Co Redburn assumed coverage on Astera Labs in a research note on Friday, May 1st. They set a "neutral" rating and a $153.00 target price for the company. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Astera Labs has an average rating of "Moderate Buy" and an average price target of $229.65.

Astera Labs Trading Up 2.1%

The firm has a market cap of $34.22 billion, a price-to-earnings ratio of 134.99, a price-to-earnings-growth ratio of 4.21 and a beta of 3.35. The stock's 50 day moving average is $143.77 and its 200 day moving average is $153.99.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.07. Astera Labs had a return on equity of 19.36% and a net margin of 26.72%.The company had revenue of $308.36 million during the quarter, compared to analysts' expectations of $292.19 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The business's revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. On average, equities research analysts predict that Astera Labs, Inc. will post 1.48 EPS for the current year.

Insider Transactions at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 10,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $107.77, for a total transaction of $1,077,700.00. Following the transaction, the general counsel owned 118,084 shares in the company, valued at $12,725,912.68. This trade represents a 7.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $107.61, for a total value of $19,692,630.00. Following the sale, the director directly owned 319,863 shares of the company's stock, valued at $34,420,457.43. This represents a 36.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,064,888 shares of company stock valued at $150,764,723. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Astera Labs

A number of hedge funds have recently bought and sold shares of ALAB. Assetmark Inc. boosted its holdings in Astera Labs by 374.1% in the 3rd quarter. Assetmark Inc. now owns 128 shares of the company's stock valued at $25,000 after purchasing an additional 101 shares during the period. Reflection Asset Management bought a new position in shares of Astera Labs during the fourth quarter worth approximately $25,000. Smartleaf Asset Management LLC raised its position in shares of Astera Labs by 422.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 188 shares of the company's stock valued at $32,000 after buying an additional 152 shares in the last quarter. Hilltop National Bank raised its position in shares of Astera Labs by 100.0% in the fourth quarter. Hilltop National Bank now owns 200 shares of the company's stock valued at $33,000 after buying an additional 100 shares in the last quarter. Finally, Aventura Private Wealth LLC bought a new stake in shares of Astera Labs in the fourth quarter valued at approximately $33,000. 60.47% of the stock is owned by institutional investors.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.